Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study

Table 5

Change in PSA levels from baseline to each visit for patients with moderate to severe LUTS at baseline.

	At baseline ( = 164)
	0 to <4 ng/mL	≥4 to <10 ng/mL	≥10 ng/mL
At week 24 ( = 140)
( < 0.001 versus baseline)
0 to <4 ng/mL	19 (13.6%)	46 (32.9%)	58 (41.4%)
≥4 to <10 ng/mL	0 (0%)	1 (0.7%)	5 (3.6%)
≥10 ng/mL	0 (0%)	0 (0%)	11 (7.9%)
At week 48 ( = 142)
( < 0.001 versus baseline)
0 to <4 ng/mL	17 (12.0%)	51 (35.9%)	62 (43.7%)
≥4 to <10 ng/mL	1 (0.7%)	1 (0.7%)	2 (1.4%)
≥10 ng/mL	0 (0%)	0 (0%)	8 (5.6%)
At last available visit ( = 157)
( < 0.001 versus baseline)
0 to <4 ng/mL	18 (11.5%)	54 (34.4%)	70 (44.6%)
≥4 to <10 ng/mL	1 (0.6%)	1 (0.6%)	3 (1.9%)
≥10 ng/mL	0 (0%)	0 (0%)	10 (6.4%)